secwatch / observer
8-K filed March 31, 2023, 7:59 PM ET ticker FBRX CIK 0001419041
earnings confidence high sentiment neutral materiality 0.65

Forte Biosciences reports FY 2022 net loss of $13.9M; advancing FB-102 toward clinic in late 2023/early 2024

Forte Biosciences, Inc.

2023-Q1 EPS reported -$0.32
item 2.02item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Forte Biosciences, Inc. reported the fourth quarter and fiscal year ended December 31, 2022 results: net income Net losses were $13.9 million and $21.7 million, and net losses per share were ($0.80) and ($1.55) for the years ended D, EPS net losses per share were ($0.80) and ($1.55) for the years ended December 31, 2022 and 2021, respectively..

Period
the fourth quarter and fiscal year ended December 31, 2022
Net income
Net losses were $13.9 million and $21.7 million, and net losses per share were ($0.80) and ($1.55) for the years ended D
EPS
net losses per share were ($0.80) and ($1.55) for the years ended December 31, 2022 and 2021, respectively.
Result
reported results
Exact text from the filing
On March 31, 2023, Forte Biosciences, Inc. issued a press release reporting its financial results for the fourth quarter and fiscal year ended December 31, 2022.
View on SEC.gov

Browse all earnings releases →

Forte Biosciences, Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-088024
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.